Comparative Pharmacology
Head-to-head clinical analysis: HUMEGON versus PERGONAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HUMEGON versus PERGONAL.
HUMEGON vs PERGONAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HUMEGON (menotropins) is a purified preparation of gonadotropins (follicle-stimulating hormone, FSH, and luteinizing hormone, LH) extracted from the urine of postmenopausal women. It acts by stimulating ovarian follicular growth and maturation in women and spermatogenesis in men via binding to FSH and LH receptors on target cells.
Pergonal (menotropins) is a purified preparation of gonadotropins (follicle-stimulating hormone, FSH, and luteinizing hormone, LH) extracted from postmenopausal urine. It stimulates ovarian follicular growth and maturation in women and spermatogenesis in men by acting on specific gonadal receptors.
75 to 150 IU subcutaneously or intramuscularly once daily for 7 to 12 days, adjusted based on follicular response.
Intramuscular administration: 75 IU daily for 7-12 days, then 5,000-10,000 IU hCG 24 hours after last dose.
None Documented
None Documented
Terminal half-life approximately 23-24 hours (range 20-30 h) for FSH and LH activity; clinical significance: once-daily dosing achieves steady-state in 4-5 half-lives (approx. 5 days).
Terminal elimination half-life approximately 24-36 hours; clinical context: supports daily dosing in ovulation induction protocols.
Primarily renal (90-95% as intact hormone and metabolites); biliary/fecal excretion minor (<5%).
Primarily renal: 70-80% as unchanged drug and metabolites within 24 hours; biliary/fecal excretion accounts for <5%.
Category C
Category C
Gonadotropin
Gonadotropin